Paragon Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Paragon Biosciences's estimated annual revenue is currently $4.5M per year.
- Paragon Biosciences's estimated revenue per employee is $155,000
Employee Data
- Paragon Biosciences has 29 Employees.
- Paragon Biosciences grew their employee count by 0% last year.
Paragon Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Information Technology | Reveal Email/Phone |
Paragon Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Paragon Biosciences?
Paragon is a life science innovator that creates, invests in and builds bioscience companies. We solve complex challenges by advancing science. Paragon focuses on four areas of life science innovation including artificial intelligence, gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies in development. Paragon stands at the intersection of human need, life science, and company creation.
keywords:N/AN/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Paragon Biosciences News
HARMONY BIOSCIENCES ANNOUNCES DATE OF FIRST ... WFMZ
Evozyne Announces Multi-Target Research Collaboration and ... PR Newswire
Emalex Biosciences to Present Positive Results for Pediatric ... PR Newswire
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3M | 29 | -6% | N/A |
#2 | $5.1M | 29 | -3% | N/A |
#3 | $6M | 29 | 4% | N/A |
#4 | $3.3M | 29 | -9% | N/A |
#5 | $2M | 29 | 12% | N/A |